Media Center

CLS is committed to providing the media with timely and accurate information related to California’s life sciences ecosystem. CLS welcomes all media inquiries from news organizations and reporters. Members of the media interested in speaking with CLS opinion leaders on issues of public policy, life sciences innovation, or issues related to the life sciences ecosystem in California, please contact our communication department.

Media Contact: [email protected]

AB 1887 Signed Into Law

Sep 28, 2026

Governor Gavin Newsom has signed AB 1887 into law — a critical step forward for California's rare disease community. This legislation eliminates prior authorization and step therapy delays for FDA-approved rare disease treatments, ensuring patients can access the care their doctors prescribe without unnecessary insurance red tape.

Read More

California Life Sciences Announces Fall 2026 FAST California Cohort

Sep 11, 2026

California Life Sciences (CLS) today announced that 11 companies have been accepted into the Fall 2026 cohort of FAST California, the association’s flagship innovation and entrepreneurship program.

Read More

California Life Sciences (CLS) Elects New Board Chair, Vice Chair, and Four Members to Board of Directors

Sep 8, 2026

California Life Sciences (CLS) today announced new leadership and four new members for its Board of Directors.

Read More

A treatment in search of a disease – Legislation unnecessarily threatens California’s leadership in life sciences

Jul 27, 2026

The success and productivity of California’s life sciences ecosystem rely on its unique, interconnected structure.

Read More

At BIO 2026, industry wrestled with Washington politics, and making AI work better

Jun 25, 2026

Executives talked about strategies to adapt to Trump’s way of governance, and the rising cost of AI

Read More

California Life Sciences’ Statement on HHS Clinical Trial Effort

Jun 23, 2026

Read CLS President & CEO Mike Guerra's statement on the Department of Health and Human Services' coordinated effort to restore U.S. leadership in clinical trials.

Read More